DE MERCANTI, STEFANIA FEDERICA
DE MERCANTI, STEFANIA FEDERICA
SCIENZE CLINICHE E BIOLOGICHE
A case of Hyperekplexia with positive anti GlyR antibodies: PERM syndrome
2009-01-01 Giulia Contessa; Stefania De Mercanti; Lorenza Delfico; Rossella Sciolla; mario Coletti Moja; Bruno Ferrero; Cinzia Ferrero; Paolo Ripellino; Emanuela Viglietta; Delon La Puma; Luca Durelli
A real-world study of Alemtuzumab in a cohort of Italian patients
2019-01-01 Sacca, F; Russo, CV; Frau, J; Annovazzi, P; Signoriello, E; Bonavita, S; Grasso, R; Clerico, M; Cordioli, C; Laroni, A; Capobianco, M; Clerici, VT; Sartori, A; Cavalla, P; Maniscalco, GT; La Gioia, S; Caleri, F; Giugno, A; Iodice, R; Carotenuto, A; Cocco, E; Fenu, G; Zaffaroni, M; Baronicini, D; Lus, G; Gallo, A; De Mercanti, SF; Lapucci, C; Di Francescantonio, V; Sormani, MP; Signori, A
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months
2016-01-01 Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation
2016-01-01 Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials
2012-01-01 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L.
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study
2018-01-01 Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Via, AG; Lamberti, A; Lanzillo, R; Bonavita, S; Esposito, S; Giordano, M; Cocolin, LS; Clerico, M
Are arterial hypertension and diabetes modifiers of ALS phenotype and outcome? A population-based study
2015-01-01 Calvo, A; Moglia, C; Canosa, A; Bertuzzo, D; Galmozzi, F; Cugnasco, P; Clerico, M; De Mercanti, S; Bersano, E; Cammarosano, S; Ilardi, A; Manera, U; Sideri, R; Marinou, K; Bottacchi, E; Pisano, F; Cantello, R; Mazzini, L; Mora, G; Chiò, A
Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient
2015-01-01 De Mercanti, S; Artusi, Ca; Clerico, M; Iudicello, M; Vacca, A; Virgilio, E; Durelli, L
Atypical presentation of superficial sclerosis successfully treated with iron chelation
2013-01-01 De Mercanti S; Iudicello M; Clerico M; Piazza F; Gibbin M; Longo F; Durelli L
Botulinum Toxin A for Treatment of Sialorrhea in neurologic diseases: 2-year Prospective Study
2015-01-01 Barbero, P; Artusi, Ca; De Mercanti, S; Tinivella, M; Busso, M; Clerico, M; Durelli, L
can the increase of T-helper 17 Lymphocyte percentage in peripheral blood anticipate a relapse in relapsing remitting multiple sclerosis?
2010-01-01 Luca Durelli; Marinella Clerico; Simona Rolla; Giulia Contessa; Stefania De Mercanti; Antoni Uccelli; Mauro Zaffaroni; Paola Cavalla; Luciano Rinaldi; Cristoforo Comi; Roberto Cavallo; Luisa Sosso; Francesco Novelli
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation
2017-01-01 Iannello A., Ferrero G., Maglione A., Cordero F., Rolla S., Bardina V., De Mercanti S., Durelli L., Clerico M., Cutrupi S.
Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report
2016-01-01 De Mercanti, S; Durelli, L; Iudicello, M; Artusi, Ca; Barbero, P; Guerrasio, A; Clerico, M
Cytomegalovirus reactivation during alemtuzumab treatment in a patient with multiple sclerosis
2016-01-01 De Mercanti, S.F.; Durelli, L.; Iudicello, M.; Artusi, C.A.; Barbero, P.; Guerrasio, A.; Clerico, M.
Epigenetic mechanisms regulate T helper 17 and T regulatory cells during pregnancy in multiple sclerosis.
2018-01-01 Rolla Simona, Bardina Valentina, Iannello Andrea, Maglione Alessandro, De Mercanti Stefania, Puorro Giorgia, Lanzillo Roberta, Cordioli Cinzia, Turrini Mariavittoria, De Bortoli Michele, Cutrupi Santina, Clerico Marinella.
Epigenetic Therapy for Friedreich’s Ataxia: A Phase I Clinical Trial
2014-01-01 Jacoby, D.; Rusche, J.; Iudicello, M.; De Mercanti, S.; Clerico, M; Gibbin, M.; Longo, F.; Miao, W.; Rai, M.; Piga, A.; Pandolfo, M.; Durelli, L.
Estrogen receptor alpha in peripheral blood lymphocytes of multiple sclerosis patients: a pivotal study of its role in pregnant patients
2015-01-01 Clerico, M; Cutrupi, S; Rolla, S; De Mercanti, S; Iannello, A; Virgilio, E; De Bortoli, M; Durelli, L
Estrogen receptor alpha regulates key genomic regions of t-helper 17 and T-regulatory cells in Multiple Sclerosis: a new potential biomarker of disease activity.
2016-01-01 Marinella, Clerico; Santina, Cutrupi; De Mercanti Stefania, ; Simona, Rolla; Andrea, Iannello; Giulio, Ferrero; Bortoli Michele, De; Luca, Durelli
Estrogen Receptor Alpha Regulates Key Genomic Regions of Thelper 17 and T Regulatory Cells in Multiple Sclerosis: A New Potential Biomarker of Disease Activity
2016-01-01 Clerico, M.; Cutrupi, S.; De Mercanti, S.; Rolla, S.; Iannello, A.; Ferrero, G.; De Bortoli, M.; Durelli, L. .
Estrogen receptor alpha role in multiple sclerosis patients: trying to identify a new biomarker of disease activity
2015-01-01 Clerico, M; Cutrupi, S; De Mercanti, S; Virgilio, E; Iannello, A; De Bortoli, M; Durelli, L
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
A case of Hyperekplexia with positive anti GlyR antibodies: PERM syndrome | 2009 | Giulia Contessa; Stefania De Mercanti; Lorenza Delfico; Rossella Sciolla; mario Coletti Moja; Bruno Ferrero; Cinzia Ferrero; Paolo Ripellino; Emanuela Viglietta; Delon La Puma; Luca Durelli | |
A real-world study of Alemtuzumab in a cohort of Italian patients | 2019 | Sacca, F; Russo, CV; Frau, J; Annovazzi, P; Signoriello, E; Bonavita, S; Grasso, R; Clerico, M; Cordioli, C; Laroni, A; Capobianco, M; Clerici, VT; Sartori, A; Cavalla, P; Maniscalco, GT; La Gioia, S; Caleri, F; Giugno, A; Iodice, R; Carotenuto, A; Cocco, E; Fenu, G; Zaffaroni, M; Baronicini, D; Lus, G; Gallo, A; De Mercanti, SF; Lapucci, C; Di Francescantonio, V; Sormani, MP; Signori, A | |
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months | 2016 | Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M | |
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation | 2016 | Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M | |
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials | 2012 | De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L. | |
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study | 2018 | Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Via, AG; Lamberti, A; Lanzillo, R; Bonavita, S; Esposito, S; Giordano, M; Cocolin, LS; Clerico, M | |
Are arterial hypertension and diabetes modifiers of ALS phenotype and outcome? A population-based study | 2015 | Calvo, A; Moglia, C; Canosa, A; Bertuzzo, D; Galmozzi, F; Cugnasco, P; Clerico, M; De Mercanti, S; Bersano, E; Cammarosano, S; Ilardi, A; Manera, U; Sideri, R; Marinou, K; Bottacchi, E; Pisano, F; Cantello, R; Mazzini, L; Mora, G; Chiò, A | |
Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient | 2015 | De Mercanti, S; Artusi, Ca; Clerico, M; Iudicello, M; Vacca, A; Virgilio, E; Durelli, L | |
Atypical presentation of superficial sclerosis successfully treated with iron chelation | 2013 | De Mercanti S; Iudicello M; Clerico M; Piazza F; Gibbin M; Longo F; Durelli L | |
Botulinum Toxin A for Treatment of Sialorrhea in neurologic diseases: 2-year Prospective Study | 2015 | Barbero, P; Artusi, Ca; De Mercanti, S; Tinivella, M; Busso, M; Clerico, M; Durelli, L | |
can the increase of T-helper 17 Lymphocyte percentage in peripheral blood anticipate a relapse in relapsing remitting multiple sclerosis? | 2010 | Luca Durelli; Marinella Clerico; Simona Rolla; Giulia Contessa; Stefania De Mercanti; Antoni Uccelli; Mauro Zaffaroni; Paola Cavalla; Luciano Rinaldi; Cristoforo Comi; Roberto Cavallo; Luisa Sosso; Francesco Novelli | |
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation | 2017 | Iannello A., Ferrero G., Maglione A., Cordero F., Rolla S., Bardina V., De Mercanti S., Durelli L., Clerico M., Cutrupi S. | |
Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report | 2016 | De Mercanti, S; Durelli, L; Iudicello, M; Artusi, Ca; Barbero, P; Guerrasio, A; Clerico, M | |
Cytomegalovirus reactivation during alemtuzumab treatment in a patient with multiple sclerosis | 2016 | De Mercanti, S.F.; Durelli, L.; Iudicello, M.; Artusi, C.A.; Barbero, P.; Guerrasio, A.; Clerico, M. | |
Epigenetic mechanisms regulate T helper 17 and T regulatory cells during pregnancy in multiple sclerosis. | 2018 | Rolla Simona, Bardina Valentina, Iannello Andrea, Maglione Alessandro, De Mercanti Stefania, Puorro Giorgia, Lanzillo Roberta, Cordioli Cinzia, Turrini Mariavittoria, De Bortoli Michele, Cutrupi Santina, Clerico Marinella. | |
Epigenetic Therapy for Friedreich’s Ataxia: A Phase I Clinical Trial | 2014 | Jacoby, D.; Rusche, J.; Iudicello, M.; De Mercanti, S.; Clerico, M; Gibbin, M.; Longo, F.; Miao, W.; Rai, M.; Piga, A.; Pandolfo, M.; Durelli, L. | |
Estrogen receptor alpha in peripheral blood lymphocytes of multiple sclerosis patients: a pivotal study of its role in pregnant patients | 2015 | Clerico, M; Cutrupi, S; Rolla, S; De Mercanti, S; Iannello, A; Virgilio, E; De Bortoli, M; Durelli, L | |
Estrogen receptor alpha regulates key genomic regions of t-helper 17 and T-regulatory cells in Multiple Sclerosis: a new potential biomarker of disease activity. | 2016 | Marinella, Clerico; Santina, Cutrupi; De Mercanti Stefania, ; Simona, Rolla; Andrea, Iannello; Giulio, Ferrero; Bortoli Michele, De; Luca, Durelli | |
Estrogen Receptor Alpha Regulates Key Genomic Regions of Thelper 17 and T Regulatory Cells in Multiple Sclerosis: A New Potential Biomarker of Disease Activity | 2016 | Clerico, M.; Cutrupi, S.; De Mercanti, S.; Rolla, S.; Iannello, A.; Ferrero, G.; De Bortoli, M.; Durelli, L. . | |
Estrogen receptor alpha role in multiple sclerosis patients: trying to identify a new biomarker of disease activity | 2015 | Clerico, M; Cutrupi, S; De Mercanti, S; Virgilio, E; Iannello, A; De Bortoli, M; Durelli, L |